What is the likely diagnosis and recommended management for a patient with ferritin 332 µg/L, serum iron 179 µg/dL, transferrin saturation 51 %, total iron‑binding capacity 351 µg/dL, bilirubin 1.6 mg/dL, alanine aminotransferase 44 U/L, aspartate aminotransferase 29 U/L, and alkaline phosphatase 46 U/L?

Likely Diagnosis: Hereditary Hemochromatosis (HFE-Related)

This patient has biochemical iron overload with elevated transferrin saturation (51%) and moderately elevated ferritin (332 µg/L), strongly suggesting hereditary hemochromatosis that requires HFE genetic testing and initiation of therapeutic phlebotomy. 1, 2

Diagnostic Interpretation

Iron Parameters Analysis

• Transferrin saturation of 51% is the key diagnostic finding - this exceeds the 45% threshold used to identify patients requiring further evaluation for hemochromatosis 2
• Ferritin of 332 µg/L is moderately elevated and, combined with elevated transferrin saturation, indicates iron overload rather than inflammation alone 1
• The combination of elevated transferrin saturation with elevated ferritin is characteristic of hemochromatosis, where inappropriately low hepcidin leads to disturbed plasma iron homeostasis 1

Liver Enzyme Pattern

• Mildly elevated ALT (44 U/L) with normal AST (29 U/L) and normal alkaline phosphatase (46 U/L) suggests early hepatic iron deposition without significant inflammation or advanced fibrosis 2
• Since ferritin is <1000 µg/L and liver enzymes show only mild elevation, this patient likely does not have advanced liver disease or cirrhosis 2
• Mildly elevated total bilirubin (1.6 mg/dL) may reflect early hepatic involvement but is nonspecific 3

Recommended Diagnostic Workup

Immediate Next Steps

1. Order HFE genetic testing to confirm C282Y homozygosity or C282Y/H63D compound heterozygosity 1, 2
2. Liver biopsy is NOT required in this patient since ferritin is <1000 µg/L and there are no indicators of significant liver disease (only mild ALT elevation) 2
3. Consider hepatic MRI with iron quantification if the diagnosis remains unclear after genetic testing, or to assess for extrahepatic organ involvement 1

Additional Evaluation

• Screen for end-organ complications: assess for diabetes (fasting glucose, HbA1c), cardiac function (ECG, echocardiogram if symptomatic), joint symptoms, and hypogonadism 2
• Evaluate for secondary causes if HFE testing is negative: assess for alcohol consumption, metabolic syndrome features (waist circumference, lipid panel), and other liver diseases 1, 3

Management Recommendations

Therapeutic Phlebotomy Protocol

Initiate weekly therapeutic phlebotomy immediately - treatment should not be delayed pending genetic test results given the clear biochemical evidence of iron overload 2

Induction Phase

• Remove 400-500 mL of blood weekly or every 2 weeks, depending on body weight and tolerance 1, 2
• Check hemoglobin/hematocrit before each phlebotomy session 2
• Do not allow hemoglobin to fall by more than 20% of baseline - if hemoglobin drops below 12 g/dL, decrease frequency; discontinue if <11 g/dL 1, 2
• Monitor ferritin every 10-12 phlebotomies (approximately every 3 months) initially 2
• When ferritin decreases below 200 µg/L, check ferritin every 1-2 sessions 1
• Target ferritin of 50-100 µg/L to complete the induction phase 1, 2

Maintenance Phase

• After reaching target ferritin, continue phlebotomy at intervals (every 1-4 months) to maintain ferritin between 50-100 µg/L 1, 2
• Some experts accept more relaxed targets of <200 µg/L for women and <300 µg/L for men during maintenance, particularly in elderly patients who tolerate aggressive depletion poorly 1
• Monitor ferritin every 6 months during maintenance to ensure levels remain in target range 1
• The frequency of maintenance phlebotomy varies widely - some patients require monthly sessions while others need only 1-2 units removed per year 2

Dietary and Lifestyle Modifications

Dietary changes should NOT substitute for phlebotomy but serve as adjunctive measures 1

• Avoid iron supplements and iron-fortified foods 1, 2
• Avoid supplemental vitamin C, especially before iron depletion is achieved, as it accelerates iron mobilization and can increase oxidant stress 1, 2
• Limit red meat consumption 1
• Restrict alcohol intake during iron depletion - patients with iron overload and liver abnormalities should avoid or consume very little alcohol 1
• Avoid raw shellfish due to risk of Vibrio vulnificus infection in iron-overloaded patients 2
• Consider monitoring plasma folate and cobalamin in patients requiring numerous venesections; supplement if deficient 1

Important Clinical Considerations

Prognosis and Monitoring

• Life expectancy is normal if treatment begins before development of cirrhosis and diabetes 2, 3
• This patient's ferritin of 332 µg/L suggests early disease without cirrhosis, making prognosis excellent with appropriate treatment 2
• Hepatic fibrosis may reverse in approximately 30% of cases with adequate iron removal, but established cirrhosis does not reverse 2
• No screening for hepatocellular carcinoma is needed unless cirrhosis develops, as HCC is exceptionally rare in noncirrhotic hemochromatosis 2

Common Pitfalls to Avoid

• Do not delay treatment waiting for genetic confirmation - biochemical evidence is sufficient to begin phlebotomy 2
• Do not over-treat to the point of iron deficiency - stop when ferritin reaches 50-100 µg/L range 1, 2
• Do not assume all patients need the same maintenance schedule - iron reaccumulation rates vary widely 2
• Transferrin saturation may remain elevated (>50%) even when ferritin is in target range - this is expected in HFE-related hemochromatosis and does not necessarily require more aggressive phlebotomy 1
• Ferritin can be falsely elevated by inflammation, but the elevated transferrin saturation in this case confirms true iron overload rather than inflammatory hyperferritinemia 1, 4

If Genetic Testing is Negative

• Investigate for dysmetabolic iron overload syndrome (metabolic syndrome with mild hepatic iron increase) - this is actually the most common iron overload condition 3
• Consider compound heterozygosity (C282Y/H63D) or H63D homozygosity, which can cause mild-to-moderate iron overload, especially with additional risk factors like alcohol or fatty liver 1
• Evaluate for secondary iron overload from chronic liver disease, though the pattern here (elevated transferrin saturation) is more consistent with primary hemochromatosis 1, 5